Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 11Carcinoma, Renal Cell 8Lymphoma 7Neoplasm Metastasis 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Hematologic Neoplasms 5Glioblastoma 5Anus Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3HIV Infections 3Gliosarcoma 3Esophageal Neoplasms 3

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Muscle Invasive Bladder Urothelial Carcinoma × Nivolumab × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡